Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

Los Angeles, California

Phase 1 colorectal cancer trials in Los Angeles, CA

58 Phase 1 colorectal cancer studies are recruiting participants at sites in Los Angeles as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Los Angeles at a glance

  • 58 studies are recruiting at a site in Los Angeles.
  • By phase: Phase 1 (29), Phase 1/2 (29).
  • By sponsor: industry (51), university, hospital or other (6), government (1).
  • Most recent update to one of these records: November 17, 2026.

Studies recruiting in Los Angeles

Basic details from each study's public record (the 30 most recently updated of 58). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study sites
    The Angeles clinic - A cedars SINAI AFFILIATE · USC Norris Comprehensive Cancer Center
    Registry record
    NCT05786924 · updated
  2. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    USC Norris Comprehensive Cancer Center
    Registry record
    NCT06253871 · updated
  3. A Study of VET3-TGI in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    KaliVir Immunotherapeutics
    Study site
    USC/Norris Comprehensive Cancer Center
    Registry record
    NCT06444815 · updated
  4. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    Ellison Medical Institute · University of California Los Angeles · Valkyrie Clinical Trials
    Registry record
    NCT06324357 · updated
  5. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    START Los Angeles
    Registry record
    NCT07488676 · updated
  6. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Vividion Therapeutics, Inc.
    Study site
    START Los Angeles
    Registry record
    NCT06004245 · updated
  7. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT07458347 · updated
  8. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT07020221 · updated
  9. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    USC / Norris Comprehensive Cancer Center
    Registry record
    NCT06102902 · updated
  10. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT04929223 · updated
  11. Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Jonsson Comprehensive Cancer Center
    Study site
    UCLA / Jonsson Comprehensive Cancer Center
    Registry record
    NCT04703101 · updated
  12. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    USC Norris Comprehensive Cancer Center
    Registry record
    NCT07397338 · updated
  13. A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of California, Los Angeles UCLA
    Registry record
    NCT05379595 · updated
  14. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    START Los Angeles
    Registry record
    NCT07542704 · updated
  15. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    University of California, Los Angeles
    Registry record
    NCT07584226 · updated
  16. A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

    • Phase 1/2
    • Ages 18 to 75
    • All sexes
    Sponsor
    VM Discovery, Inc.
    Study site
    The Angeles Clinic and Research Institute (#601)
    Registry record
    NCT07636785 · updated
  17. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Eikon Therapeutics
    Study site
    California Research Institute (CRI)
    Registry record
    NCT07262619 · updated
  18. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCLA ( Site 0317)
    Registry record
    NCT06428409 · updated
  19. A Study of MGC026 in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    MacroGenics
    Study site
    The Angeles Clinic and Research Institute
    Registry record
    NCT06242470 · updated
  20. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study sites
    UCLA Department of Medicine - Hematology/Oncology · VA Greater Los Angeles Healthcare System
    Registry record
    NCT06710756 · updated
  21. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Los Angeles Cancer Network
    Registry record
    NCT06330064 · updated
  22. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    USC Norris Comprehensive Cancer Center
    Registry record
    NCT04657068 · updated
  23. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated
  24. SMP-3124LP in Adults With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Sumitomo Pharma America, Inc.
    Study site
    Cedars Sinai Medical Center
    Registry record
    NCT06526819 · updated
  25. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study sites
    Cedars-Sinai Medical Center · UCLA Department of Medicine · University of Southern California
    Registry record
    NCT06026410 · updated
  26. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    University of California, Los Angeles (UCLA)
    Registry record
    NCT05919264 · updated
  27. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Bicara Therapeutics
    Study site
    Keck School of Medicine of USC
    Registry record
    NCT04429542 · updated
  28. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study sites
    UCLA Jonsson Comprehensive Cancer Center · USC Norris Comprehensive Cancer Center
    Registry record
    NCT04585750 · updated
  29. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study site
    University of California Los Angeles
    Registry record
    NCT06625775 · updated
  30. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05877599 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Ask about studies near Los Angeles

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call